|6 Months Ended|
Jun. 30, 2021
|Subsequent Events [Abstract]|
10. Subsequent Event
In August 2021, the Company entered into an agreement with a contract manufacturing organization for the purchase of plasmids to be used in vector manufacturing for a total cost of $1,100, expected to be incurred during 2021 and 2022.
No definition available.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef